| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
|
Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
|
Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
|
Park K;Bennouna J;Boyer M;Hida T;Hirsh V;Kato T;Lu S;Mok T;Nakagawa K;O'Byrne K;Paz-Ares L;Schuler M;Sibilot D.M;Tan E.-H;Tanaka H;Wu Y.-L;Chih-Hsin Yang;Zhang L;Zhou C;M?rten A;Tang W;Yamamoto N.; Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
|
Park K;Bennouna J;Boyer M;Hida T;Hirsh V;Kato T;Lu S;Mok T;Nakagawa K;O'Byrne K;Paz-Ares L;Schuler M;Sibilot D.M;Tan E.-H;Tanaka H;Wu Y.-L;Chih-Hsin Yang;Zhang L;Zhou C;M?rten A;Tang W;Yamamoto N.; Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
|
Solomon B.J; Shaw A.T.; Ignatius Ou S.-H; Thurm H; Peltz G; Besse B; Bauer T.M; Felip E; Soo R.A; Camidge D.R; Chiari R; Bearz A; Chia-Chi Lin; Gadgeel S.M; Riely G.J; Tan E.H; Seto T; James L.P; Clancy J.S; Abbattista A; Martini J.-F; Chen J |
